布地奈德联合多索茶碱治疗慢性阻塞性肺疾病的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Budesonide combined with Doxofylline in the treatment of chronic obstructive pulmonary disease.Methods A total of 90 patients with chronic obstructive pulmonary disease admitted to Liangxiang Hospital of Fangshan District, Beijing from May 2017 to June 2019 were selected as the research objects.According to random number table method, they were divided into the observation group and the control group,with 45 cases in each group.The observation group was given Budesonide combined with Doxotheophylline, while the control group was given routine treatment, the treatment period was 10 d.The therapeutic effect, pulmonary function indexes, arterial blood gas indexes and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.78%, which was higher than that of the control group(68.89%), and the difference was statistically significant (P＜0.05).There were no significant differences in forced expiratory volume in one second (FEV1) and forced expiratory volume in one second/forced vital capacity (FEV1/FVC) between the two groups before treatment (P＞0.05).After treatment, FEV1 and FEV1/FVC in the two groups were higher than those before treatment, FEV1 and FEV1/FVC in the observation group were higher than those in the control group,and the differences were statistically significant (P＜0.05).Before treatment, there were no significant differences in blood oxygen partial pressure (PaO2) and arterial carbon dioxide partial pressure (PaCO2) between the two groups (P＞0.05).After treatment, PaO2 levels in two groups were higher than those before treatment, PaCO2 levels were lower than those before treatment, PaO2 in the observation group was higher than that in the control group, PaCO2 was lower than that in the control group, and the differences were statistically significant (P＜0.05).The total incidence of adverse reactions in the observation group was 6.67%, which was lower than that in control group (22.22%), and the difference was statistically significant (P＜0.05).Conclusion Budesonide combined with Doxofylline can be used for the treatment of chronic obstructive pulmonary disease with fewer adverse events.It is safe and has clinical application value.

Key words： Budesonide Doxofylline Chronic obstructive pulmonary disease Clinical application

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Tie-gang
	NIE Qing-rong

Cite this article:

JIA Tie-gang,NIE Qing-rong. Clinical effect of Budesonide combined with Doxofylline in the treatment of chronic obstructive pulmonary disease[J]. 中国当代医药, 2021, 28(8): 52-54转58.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I8/52

[1]	边旭青.多索茶碱联合噻托溴铵对慢性阻塞性肺病患者肺功能、气道重塑及抗氧化功能的影响[J].临床医学研究与实践，2019，4（35）：44-46.
[2]	Fletcher C，Peto R.The natural history of chronic airflow obstruction[J].Br Med J，1977，1（6077）：1645-1648.
[3]	陆杏妍，陈丹纯.布地奈德联合异丙托溴铵雾化辅助治疗慢性阻塞性肺疾病的疗效及对动脉血气指标的影响[J].临床合理用药，2020，13（8）：45-46.
[4]	牧坤，高莹慧，苗淑贤，等.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国实用医药，2017，12（33）：104-105.
[5]	潘宜，黄晓颖.布地奈德联合沙丁胺醇和异丙托溴铵治疗慢性阻塞性肺疾病急性发作期的临床研究[J].中国临床药理学杂志，2016，32（15）：1347-1349.
[6]	夏婉飞.多索茶碱与噻托溴铵粉联合治疗对慢阻肺患者肺功能的价值分析[J].中国现代药物应用，2019，13（23）：152-153.
[7]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中国医学前沿杂志，2014，6（2）：67-79.
[8]	王晓玲.多索茶碱与噻托溴铵用于COPD 治疗的临床效果研究[J].甘肃科技，2020，36（12）：153-155.
[9]	Agustí A，Faner R.COPD beyond smoking：new paradigm，novel opportunities[J].Lancet Respir Med，2018，6（5）：324-326.
[10]	Agustí A，Faner R.Lung function trajectories in health and disease[J].Lancet Respir Med，2019，4：358-364.
[11]	肖秀国.多索茶碱与噻托溴铵粉联合方案治疗慢阻肺的应用与肺功能分析[J].中国医药指南，2019，17（12）：99-100.
[12]	付云杰.多索茶碱与噻托溴铵粉联合治疗慢阻肺对肺功能的影响[J].中国现代医生，2019，57（8）：44-45，48.
[13]	Ferguson GT，Tashkin DP，Sko rby T，et al.Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease：The 6-month，randomized RISE （Revealing the Impact of Symbicort in reducing Exacerbations in COPD） study[J].Respir Med，2017，132：31-41.
[14]	陈梅鹃，王滔，王利，等.布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗对慢性阻塞性肺疾病急性加重期疗效观察[J].解放军医学院学报，2018，39（10）：877-880.
[15]	李玲.多索茶碱联合噻托溴铵治疗慢性阻塞性肺疾病的临床效果[J].中国民康医学，2019，31（4）：7-8，14.
[16]	于传勇.多索茶碱与噻托溴铵粉联合治疗对慢阻肺患者肺功能影响的临床效果观察[J].中国社区医师，2018，34（7）：68-69.